New HCV vaccine trial aims to protect against hepatitis c
NCT ID NCT07237282
First seen Nov 19, 2025 · Last updated May 14, 2026 · Updated 18 times
Summary
This early-stage trial tests an experimental vaccine designed to protect against hepatitis C virus (HCV). The study will enroll 27 healthy adults aged 18-45 to check if the vaccine is safe and triggers a strong antibody (germ-fighting) response. Participants will receive injections in the arm and be monitored for side effects and immune markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ottawa Hospital - General Campus
Ottawa, Ontario, K1H 8L6, Canada
Contact
-
Toronto General Hospital - Toronto Centre for Liver Disease
Toronto, Ontario, M5G 2C4, Canada
Contact
-
University of Alberta Hospital
Edmonton, Alberta, T6G 2B7, Canada
Contact
Conditions
Explore the condition pages connected to this study.